.png)
Lung Cancer
Scientific Federation invites all the participants
from all over the world to attend 2nd World
Congress on Clinical Research & Biomarkers during September
17-18, 2018 Toronto, Canada.
Now a day’s cancer is very dangerous
disease and an especially lung cancer plays major role. Blood based biomarkers
have potential in cancer screening and their role could extend further from
general population risk assessment to treatment response evaluation and recurrence
monitoring. The rich content of diverse cellular and molecular elements in
blood, which provide information about the health status of an individual, makes
it an ideal compartment to develop noninvasive diagnostics for cancer. Other
common cancers, notably breast and lung cancer, lack established biomarkers
with demonstrated clinical utility in a screening setting. There is a need for
biomarkers with the required sensitivity and specificity for the detection of
frequently occurring cancer types.
Protein markers currently
in clinical use, which include Cancer antigen 125 for ovarian cancer,
Carbohydrate antigen 199 for pancreatic cancer, Carcino embryonic antigen for
colon cancer and Prostate specific antigen for prostate cancer, have
limitations with respect to their use for screening owing to low sensitivity
and specificity in early stages and inability to distinguish aggressive from
indolent tumors.
This is significantly more sensitive than the most
sensitive detection methods from electrophoretic gels with silver staining or
fluorescence staining, or the general mass spectrometry methods. Secondly, it
is known that many proteins have post-translational modifications (PTMs) and
splice variants; these different forms of the same gene product may have
different functions/enzyme activities and play very different roles in biology.
However the important information on the impact of PTM and protein splicing is
lost in the antibody, LC-MS or gel-based analysis because these platforms
cannot directly measure the functional features of the proteome. The
introduction of exogenous protein(s) from the PEP samples could potentially
supersede any rate-limiting protein function and enhance the hexokinase
activity. As such, this assay may also detect the effect of proteins from other
pathways that cross-interact with the glycol tic pathway.
0 comments: